JEMPERLI 500 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion
213824
Phase 2 small_molecule active
Quick answer
JEMPERLI 500 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion for Lung Cancer, Non-Small Cell is a Phase 2 program (small_molecule) at GlaxoSmithKline Biologicals S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline Biologicals S.A.
- Indication
- Lung Cancer, Non-Small Cell
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active